Treatments Of Covid-19 With Mesenchymal Stem Cells
Mesenchymal stem cells (MSC) of placental/umbilical origin have been FDA approval to use in with Covid-19 patients under research guidance. These are the same pluri-potent mesenchymal stem cells that Dr. Karon has been studying with applications to her specialty. Dr. Karon has also worked with reputable tissue banks who collects and cryo-preserves the stems cell right after childbirth. The mesenchymal stem cell stops the cytokine cascade that destroys the lung at the same time helps restore the lung tissue. The first target organ of MSC is lung. After which, they also go kidney and other organs.
The Lancet article shows there is no vertical transmission from mother to the baby of the virus. This is due to antibodies that are made by the placenta. They are present in amniotic fluid, umbilical cord and breast milk as a built in protection.
Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
NEW CELL THERAPY TRIAL LAUNCHES FOR PATIENTS WITH SEVERE COVID-19
U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
Israeli firm hopeful as it starts treating COVID-19 patients with placenta cells
Specific Immunoglobulin G Antibody Detected in Umbilical Blood and Amniotic Fluid from a Pregnant Woman Infected by the Coronavirus Associated with Severe Acute Respiratory Syndrome
Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records